2024
Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.
Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024 PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.Peer-Reviewed Original ResearchEndometrial carcinomaGynecologic malignanciesTyrosine kinase domainHER2-mutated non-small cell lung cancerTargeted anti-HER2 therapyNon-small cell lung cancerHigh-grade endometrioid adenocarcinomasFam-trastuzumab deruxtecanOvarian mucinous adenocarcinomaAnti-HER2 therapyAnti-HER2 drugsHER2 3+US Food and Drug AdministrationCell lung cancerEndometrial serous carcinomaSolid tumor typesStandard treatment recommendationsFood and Drug AdministrationFluorescence in situ hybridizationGynecological cancer typesEndometrial primaryMullerian originSerous carcinomaHER2 IHCEndometrioid adenocarcinoma
2010
Minimal Uterine Serous Carcinoma With Extrauterine Tumor of Identical Morphology: An Immunohistochemical Study of 13 Cases
Yan Z, Hui P. Minimal Uterine Serous Carcinoma With Extrauterine Tumor of Identical Morphology: An Immunohistochemical Study of 13 Cases. Applied Immunohistochemistry & Molecular Morphology 2010, 18: 75-79. PMID: 19956063, DOI: 10.1097/pai.0b013e3181b1d10e.Peer-Reviewed Original ResearchConceptsMinimal uterine serous carcinomaUterine serous carcinomaInvasive serous carcinomasSerous carcinomaExtrauterine tumorsExtrauterine involvementEndometrial serous carcinomaSimilar histologic featuresOvarian serous carcinomaProtein markersEndometrial primarySynchronous tumorsMetastatic lesionsHistologic featuresExtrauterine lesionsEndometrial tumorsImmunohistochemical studyProgestin receptorsHistologic examinationEstrogen receptorImmunohistochemical stainingKi-67CarcinomaMorphologic assessmentTumors